One month after GlaxoSmithKline outlined plans for the company’s future following a planned split between its pharmaceuticals and consumer health businesses, GSK posted second-quarter 2021 sales of £8.1 billion ($11.2 billion).
Mission Bio launched the company’s Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on existing products.
Swiss drugmaker Roche predicted on April 21 that demand for the company’s drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests offset a pandemic-influenced slump in its main pharmaceuticals business.
